Trial Profile
Phase II study of sunitinib in metastatic transitional cell carcinoma of the urothelium
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Feb 2016
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Bladder cancer; Urogenital cancer
- Focus Biomarker; Therapeutic Use
- 05 Mar 2010 Results of biomarker analysis presented at ASCO Genitourinary Cancers Symposium 2010.
- 08 Nov 2006 New trial record.